Date: Mar 23, 2012 Source: (
click here to go to the source)
Spring Bank Pharmaceuticals was recently issued patents for its Small Molecule Nucleic Acid Hybrid (SMNH) prodrug technology entitled "Nucleotide and Oligonucleotide prodrugs" in China, Korea, Japan and the US. The prodrug technology facilities oral delivery of SMNH compounds and oligonucleotide anlogs.